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Marine organisms have various potential applications in the area of human health. Indian coastline and EEZ is gifted with an enormous 
resources of valuables hidden into the depths of sea, and can be explored to develop valuable nutraceutical, pharmaceutical and biomedical 
SURGXFWVIRUKXPDQKHDOWKDQGZHOOEHLQJ&0)5,SLRQHHUHGLQWKHDUHDRIELRDFWLYHFRPSRXQGVIURPPDULQHÁRUDDQGIDXQDDQGFRXOGDEOH
to successfully develop a number of products for use as nutraceuticals and human health (Indian Patent Appl. No. 2064/CHE/2010, 2065/
CHE/2010, 2066/CHE/2010, 5198-99/CHE/2012). A patented product Cadalmin™ Green Mussel extract (Cadalmin™ GMe) containing anti-
LQÁDPPDWRU\SULQFLSOHVIURPPerna viridisWRFRPEDWMRLQWSDLQDUWKULWLVLQÁDPPDWRU\GLVHDVHVKDVEHHQGHYHORSHGE\&0)5,DVDQHIIHFWLYH
JUHHQDOWHUQDWLYHWRWKHV\QWKHWLFGUXJVDYDLODEOHLQWKHPDUNHW/RQJWHUPDQLPDOPRGHOH[SHULPHQWVSURYHGWKHHIÀFLHQF\DQGVDIHW\RIWKLV
nutraceutical. CadalminTM GMe is an indigenous product, and is highly cost effective with that of the imported products available in the market. 
CadalminTM*0HKDVEHHQFRPPHUFLDOL]HGZLWK$FFHOHUDWHG)UHH]H'U\LQJ&RPSDQ\3YW/WGD)'$,62)66&FHUWLÀHG
ÁDJ6KLS&RPSDQ\RI$PDOJDP*URXSRI&RPSDQLHV7KHFRPPHUFLDOL]DWLRQRI&DGDOPLQTM*0HLVVLJQLÀFDQWWRWKHPDULFXOWXUHLQGXVWU\DQG
ÀVKHUPHQDVWKLVZLOOHQKDQFHWKHGHPDQGWRSURGXFHPRUHJUHHQPXVVHOVSDUWLFXODUO\DORQJWKHZHVWFRDVWRI,QGLD
Cadalmin™ Green Algal extract (Cadalmin™ GAe) is another addition to the pipeline of the nutraceuticals developed by CMFRI as a natural remady 
WRFKURQLFMRLQWSDLQDQGDUWKULWLV&DGDOPLQ*$HFRQWDLQVQDWXUDODQGYHJHWDULDQPDULQHELRDFWLYHDQWLLQÁDPPDWRU\LQJUHGLHQWVZKLFK
have been extracted from a blend of marine macroalgae or seaweeds with an ecofriendly “green” technology. The mean lethal dose (LD50) 
of CadalminTM GAe is greater than 4000 mg/kg body weight of the mammalian subjects that indicate the safety of the product. As part of the 
further safety assessment of the extract, feeding of CadalminTM*$HHYHQDWDGRVHXSWRPJNJERG\ZHLJKWGLGQRWLQGXFHVLJQLÀFDQW
change in body weights, hematological indices, histopathological, and serum biochemical parameters between the control and treated groups 
indicating that it has no toxicity to the experimental animals. CadalminTM GAe was distributed to more than 500 patients suffering with chronic 
MRLQWSDLQDQGDUWKULWLVDQGTXHVWLRQQDLUHDQGFOLQLFDOWULDOEDVHGVWXGLHVUHYHDOHGWKDWPRUHWKDQRIWKHUHVSRQGHQWVZHUHVDWLVÀHGZLWK
the product with about 80-85% relief in joint pain and arthritis. None of the respondents reported any side effects. The diagnostically useful 
DXWRDQWLERG\WHUPHGDV5KHXPDWRLG)DFWRUV5)VZKLFKDUHWKHPRVWXVHIXOSURJQRVWLFPDUNHUIRUUKHXPDWRLGDUWKULWLVVLJQLÀFDQWO\UHGXFHG
from more than 300 IU/mL to less than 30 IU/mL within a period of two to three months of consuming the product. This product has been 
FRPPHUFLDOL]HGZLWK&HOHVWLDO%LRODEV/LPLWHGD*03:+2FHUWLÀHGSKDUPDFHXWLFDO&RPSDQ\EDVHGDW+\GHUDEDG
This album highlights the capabilities of CMFRI to undertake research on health food and nutraceutical products from marine organisms, 
which will be of direct help to combat various diseases of human beings.
Background
 5LFKGLYHUVLW\RIPDULQHRUJDQLVPVDVVXPHVDJUHDWRSSRUWXQLW\
for the discovery of new bioactive substances. 
 9DULRXVPDULQHQDWXUDOÁRUDDQGIDXQDVXFKDVELYDOYHPROOXVFV
and seaweeds have been investigated by the scientists of CMFRI 
for their plurality of bioactive properties. 
0DULQHÁRUDDQGIDXQD
An unexplored resource of 
valuable bioactive molecules
The coastline of South Indian subcontinent is bestowed with large 
DVVHPEODJHRIELYDOYHVKHOOÀVKSDUWLFXODUO\JUHHQPXVVHOPerna viridis
:LWKPRUHWKDQLGHQWLÀHGVSHFLHVWKH,QGLDQ
coasts are acknowledged for their particular richness 
in seaweeds or marine macroalgae.
&DGDOPLQ*0HFRQWDLQVQDWXUDOPDULQHELRDFWLYHDQWLLQÁDPPDWRU\
ingredients extracted from green mussel Perna viridis 
(Indian Patent Application No. 2065-2066/CHE/2010).
&DGDOPLQ*UHHQ0XVVHOH[WUDFW&DGDOPLQ*0H
A nutraceutical product developed from Perna viridis for use 
against joint pain and arthritis
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COX-I COX-II LOX-V
Aspirin
Cadalmin
TM
 GMe
Inflammatory biocatalysts
The active ingredients of Cadalmin™ GMe is effective to combat arthritic pain and 
LQÁDPPDWRU\GLVHDVHVDQGLVDQHIIHFWLYHJUHHQDOWHUQDWLYHWRV\QWKHWLFQRQVWHURLGDO
DQWLLQÁDPPDWRU\GUXJVDQGRWKHUSURGXFWVDYDLODEOHLQWKHPDUNHW
The active principles 
in Cadalmin™ GMe 
competitively inhibit 
SURLQÁDPPDWRU\
prostaglandins 
and thromboxanes 
by inhibiting 
cycloxygenases 
(COX I, II) and 
lipoxygenase 
(LOX V), and its 
activity was found to 
be comparable to the 
synthetic NSAIDs.
Cadalmin™ GMe has techniques to identify the active components and to concentrate 
them to have higher activity; it has sustained activity due to the unique biochemical 
engineering methodologies adopted to develop the product.
In vivo animal model studies revealed that the active 
principles effectively suppressed  carrageenan-
induced paw edema. 
Synthetic Drug (NSAID)
CadalminTM GMe
Time after administration (h)
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The mean lethal dose (LD50) of Cadalmin
TM GMe was greater than 4000 mg/kg body 
weight of the mammalian subjects that indicate the safety of the product. 
)HHGLQJDWDGRVHXSWRPJNJERG\ZHLJKWGLGQRWLQGXFHVLJQLÀFDQWFKDQJHLQ
hematological indices, histopathological, and serum biochemical parameters between 
the control and treated groups indicating that it has no toxicity to the experimental 
animals.
Cadalmin™ Green Mussel extract (Cadalmin™ GMe) launched by 
Dr. P. Krishnaiah, IAS, Chief Executive, National Fisheries Development Board, 
Hyderabad, at a function held at CMFRI on 19-3-2010.
CadalminTM GMe has been commercialized on 5th October 2012 with 
Accelerated Freeze Drying Company Pvt. Ltd., a FDA, ISO 22000 FSSC 
FHUWLÀHGÁDJ6KLS&RPSDQ\RI$PDOJDP*URXSRI&RPSDQLHV
This product will be commercially produced and marketed by Accelerated 
Freeze Drying Company Pvt. Ltd. under their brand name
Central Marine Fisheries Research Institute’s CadalminTM
Green Algal extract (CadalminTM GAe) from seaweed: 
A green solution to joint disorder arthritis 
:LWKPRUHWKDQLGHQWLÀHGVSHFLHVWKH,QGLDQFRDVWVDUH
acknowledged for their particular richness in seaweeds. 
The seaweeds contain a large assemblage of species that 
predominate in the coastal shelf areas of Gulf of Mannar 
region in south-eastern coast of Indian subcontinent
8QOLNHWHUUHVWULDOÁRUDVHDZHHGVKDYHQRWEHHQH[SORUHG
in detail to isolate high value bioactive compounds
CadalminTM GAe contains a unique blend of 100% natural marine 
ELRDFWLYHDQWLLQÁDPPDWRU\LQJUHGLHQWVH[WUDFWHGIURPVHOHFWHG
seaweeds with a patented ecofriendly “green” technology (Indian Patent 
Appl. Nos. 2064/CHE/2010, 5199/CHE/2012).
$QLPDOPRGHOH[SHULPHQWVSURYHGWKHHIÀFLHQF\DQGVDIHW\RIWKLVQXWUDFHXWLFDO
Time dependent in vivo animal model studies on mammalian subjects revealed the 
LQKLELWLRQRILQÁDPPDWRU\UHVSRQVHWRWKHWXQHRIE\&DGDOPLQTM GAe as 
compared to a maximum of 70% for the popular painkiller aspirin. 
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The diagnostically useful autoantibody termed as 
5KHXPDWRLG)DFWRUV5)VVLJQLÀFDQWO\UHGXFHGIURPPRUH
than 100 IU/mL to less than 20-35 IU/mL in the users. 
The mean lethal dose was greater than 4000 mg/kg body 
weight of the mammalian subjects that indicate the safety 
of the product. 
Cadalmin™ Green Algal extract has been commercialized with Celestial Biolabs 
/LPLWHGD*03:+2FHUWLÀHGSKDUPDFHXWLFDO&RPSDQ\EDVHGDW+\GHUDEDG
for a license fee of Rs. 5 lakhs and royalty of @5% on annual sale basis for 5 
years from the commencement of commercial production of the technology
Dr. G. Syda Rao, Director, Central Marine Fisheries Research Institute (CMFRI) and Dr. A.N. 
Singh, Managing Director, Celestial Biolabs limited, Hyderabad signed a Memorandum of 
Understanding (MoU) in the gracious presence of Dr. S. Ayyappan, Secretary, DARE and 
Hon’ble Director General, ICAR for commercial production and marketing of CadalminTM GAe. 
For any further information please contact:
Dr. G. Syda Rao, Director, 
Central Marine Fisheries Research Institute 
3RVW%R[1R(UQDNXODP1RUWK32.RFKL3KRQH5HVL2II
7HOHJUDP&$'$/0,1(UQDNXODP)D[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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